The American Journal of Managed Care

Prophylactic Treatment Challenges and Considerations for Hemophilia A

This is a video synopsis/summary of an Insights involving Allison Wheeler, MD. Wheeler addresses the nuanced considerations for implementing prophylaxis in patients with mild to moderate hemophilia A, ...
Business Wire

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of ...
MedPage Today

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...
Healio

FDA approves one-time gene therapy Beqvez for hemophilia B

Please provide your email address to receive an email when new articles are posted on . The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B. The ...
Healio

Fitusiran prophylaxis superior to on-demand treatment for severe hemophilia

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...
Forbes

BioMarin’s Next Roctavian Challenge Is How To Successfully Commercialize Its Gene Therapy: Warranties May Be An Option

After quite the regulatory process, with Roctavian (valoctocogene roxaparvovec) BioMarin has a potential blockbuster. On June 29th, Roctavian became the first gene therapy approved in the U.S. in the ...
Medscape

Prophylaxis Against PJP in ANCA-Associated Vasculitis Also Cuts Risk for Other Serious Infections

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...
The American Journal of Managed Care

Prophylaxis With Recombinant ADAMTS13 Demonstrates Superiority vs Standard Therapy in Congenital TTP

The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients with ...
Medscape

Antibiotic Prophylaxis During ALL Induction Halves Infection

ORLANDO, Florida ― The aggressive chemotherapy regimen given to children with acute lymphocytic leukemia (ALL) during the induction phase, which aims to push the disease into remission, also depletes ...